A Clinical Study of MIL62 in Primary Membranous Nephropathy
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics and ADA
of MIL62 compared with cyclosporine in participants with primary membranous nephropathy
(pMN).